PHARMA AND BIOTECH
The global landscape for pharmaceutical and biotechnology companies continues to experience dynamic change. These changes include price pressure, outcomes-based reimbursement, and more restrictive policy that challenge sales and R&D productivity, as well as new technologies, treatment pathways, and personalized medicine advancements that unlock avenues for growth.
The market for medical device manufacturers is changing rapidly, but innovation is only relevant if it can be delivered in a safe, effective and usable way that gives patient empowerment. This is best done in collaboration with health systems and health providers to combine technical capabilities with expertise in patient care.
DIAGNOSTICS AND LIFE SCIENCES
Few companies have the depth of experience BFG has in diagnostics – from developing pharmacy instore screening in partnership with Lloydspharmacy (bringing diabetes testing to the high street almost twenty years ago) to helping with the growth of molecular Loop-mediated isothermal amplification (LAMP) DNA amplification testing that was so important during the COVID-19 pandemic.
Next-generation sequencing, personalised medicine and point of care technology have created new opportunities for forward-thinking companies, and we can help you make the most of these.
DIGITAL HEALTH AND HEALTH IT
The biggest issue facing most NHS suppliers when looking to win new business is how to cost effectively target key decision makers. This is never easy when decision makers can often be from different areas of the Trust and include finance managers, informatics managers, clinicians as well as the Trust senior executives and even non-executive directors.
We can cost effectively raise your awareness with the right people at the right time, and make sure you have the inside track that helps give competitive advantage.